A New Moisturiser Improves DNCB-induced Atopic Dermatitis-like Symptoms and Restores Skin Barrier Function in BALB/c Mice

Author:

Foucher Christelle1,Bisson Jean-François2,Guy Martine1,Nguyen Hao Trong3,Hidalgo Sophie2,Colin Julie2,Anh Tran Tu Nguyen3,Phuong Vu Thao Thi3

Affiliation:

1. Urgo Research, Innovation & Development, Medical Development, 42 rue de Longvic, 21304 Chenôve Cedex, France

2. ETAP-Lab, Department of Inflammation-cancer, Dermatology & Toxicology, Technopôle de Nancy-Brabois, 13, rue du Bois de la Champelle - F-54500 Vandoeuvre-lès-Nancy, France

3. Ho Chi Minh City, Hospital of Dermato Venereology, 2 Nguyen Thong Street, Ward Vo Thi Sau, District 3, Ho Chi Minh City, Vietnam

Abstract

Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disorder with eczem-atous and pruritic lesions. Topical moisturisers and either topical corticosteroids or calcineurin inhibi-tors are usually recommended. Restoring the skin barrier function alleviates AD symptoms. Objective: To evaluate the efficacy of a new moisturiser compared to commercially available products in an AD murine model. Methods: Experimental AD was induced with topical applications of 2,4-DiNitroChloroBenzene (DNCB) on the shaved back skin of BALB/c mice from Day 1 to Day 38. Mice were randomized to either Vehicle/-, DNCB/-, or DNCB/Eczekalm (test product), DNCB/Atopiclair®, or DNCB/Lipikar (reference products) groups. Once daily application of either Eczekalm or Atopiclair® or Lipikar on the AD lesion was performed from Day 32 to Day 38. The AD severity index (ADSI) and animal be-haviour were monitored throughout the study. The trans-epidermal water loss (TEWL) was measured on the sacrifice day (Day 39). Results: At Day39, ADSI in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower by -70%, -68%, and -57%, respectively, as compared to DNCB/- (p < 0.001). No sign of erythema was observed in the DNCB/Eczekalm group. Mean scores of skin oedema, excoriation, and dryness in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower than in the DNCB/-. No significant difference was observed between DNCB/Eczekalm and DNCB/Lipikar groups. Mean TEWL in DNCB/Eczekalm group was significantly lower than the ones of DNCB/Atopiclair® (-43%, p < 0.001) and DNCB/Lipikar (-15%, p < 0.05). Conclusion: Eczekalm treatment significantly reduced the inflammatory effects due to AD and itch-ing episodes and restored the skin barrier function.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,General Medicine,Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3